News
May 23, 2011 - One-year results from the 278-patient multi-center, prospective, single-arm study conducted at 16 sites in Europe and Israel were presented today at the EuroPCR 2011 Congress in Paris. These results reinforce the outcomes observed with the "Next Generation" Presillon Plus (PioNIR) cobalt chromium bare metal stent systems at 9-month followup, which was the primary endpoint of the PioNIR study.
May 23, 2011
News
May 23, 2011 - OrbusNeich announced that data from multiple clinical trials supporting the safety and efficacy of the Genous Stent in cases where prolonged dual antiplatelet therapy (DAPT) is not advisable were featured today during the HEALING Symposium titled "How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy" at EuroPCR 2011 in Paris.
May 23, 2011
News
May 23, 2011 - A presentation about transcatheter aortic valve implantation (TAVI) at EuroPCR 2011 confirmed positive outcomes in patients receiving the CoreValve System from Medtronic Inc., across seven international clinical registries. The meta-analysis, undertaken by several leading international interventional cardiologists and presented during a late-breaking trial Hot Line session, summarized European data from 2,156 patients treated with the CoreValve System for severe aortic stenosis.
May 23, 2011Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024News
May 23, 2011 - Doctors in Germany are among the first to treat ischemic stroke patients outside the United States with the Revive SE, a new self-expanding blood clot retrieval and removal device designed to remove blood clots and restore blood flow to the brain in patients having a stroke.
May 23, 2011
News
May 23, 2011 -- Boston Scientific Corporation announced results from a clinical study evaluating the use of its Watchman Left Atrial Appendage Closure Device in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin. Data were presented at the annual EuroPCR Scientific Program in Paris by Martin Bergmann, M.D., Department of Cardiology at the Asklepios Klinik St. Georg in Hamburg, Germany, and principal Iinvestigator of the study.
May 23, 2011
Technology
May 20, 2011 -- Medrad Inc., a business of Bayer HealthCare, has announced the launch of the next generation Intego PET Infusion System, which features a new design that is 38 percent smaller, power-driven and includes enhancements to technologist workflow. The new Intego will be on display at the Annual Meeting of the Society of Nuclear Medicine (SNM).
May 20, 2011Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
May 20, 2011 - Boston Scientific Corporation today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25mm Promus Element Everolimus-Eluting Platinum Chromium Stent System in treating small vessel coronary disease. The study is a global, prospective, single-arm, subtrial of the PLATINUM clinical program. It compares the Promus Element Stent (2.25mm) in 94 patients with small vessels (greater than or equal to 2.25 to less than 2.50 mm reference vessel diameter and less than or equal to 28mm lesion length) to a pre-specified performance goal based on results from patients treated with the Taxus Express Paclitaxel-Eluting Stent.
May 20, 2011
News
May 20, 2011 - Edwards Lifesciences Corporation announced that clinicians continued to achieve successful one-year outcomes in high-risk or inoperable patients undergoing transcatheter aortic valve replacement during the first two years of commercialization of the Edwards Sapien valve. Data on the more than 2,300 patients enrolled in the post-market European SOURCE Registry since November 2007 were presented in a late-breaking clinical trial session today at EuroPCR 2011.
May 20, 2011
News
May 20, 2011 – e-BioMatrix post-marketing surveillance (PMS) registry information presented at EuroPCR 2011 has confirmed that BioMatrix, Biosensors’ Biolimus A9-eluting stent system with abluminal bioresorbable polymer, is safe over a 12-month period in a “real-world” patient population.
May 20, 2011Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
Feature | Stem Cell Therapies | Dave Fornell
For years researchers have experimented with stem cells in attempts to regrow myocardium in patients who suffer permanent tissue damage from myocardial infarction. A handful of companies are pushing forward with clinical trials of their technologies in an effort to show this futuristic concept has promise.
May 19, 2011
Feature | Stem Cell Therapies | Thomas F. Deering, M.D., FACC, FACP, FHRS, Piedmont Heart Institute, Atlanta
Over the last decade, cardiac stem cell therapy has shown tantalizing but as yet unrealized potential as a treatment for the left-ventricular dysfunction (LVD) that develops subsequent to myocardial infarction (MI). Experimentally, somatic stem cells of various lineages, as well as pluripotent stem cells, have been induced to transform into contractile myocytes expressing cardiac-specific proteins.
May 19, 2011Feature | Dave Fornell
Only a few years ago, separate software systems without a common interface were the industry standard to manage electrocardiograms (ECGs), hemodynamic monitoring systems in the cath lab, picture archiving and communications systems (PACS), electrophysiology, cardiac ultrasound and other areas of cardiac specialty.
May 19, 2011Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
Feature | Todd Loesch
For decades, cath lab clinicians essentially had only one option for achieving hemostasis management following a procedure – compression. That changed in the 1990s with the introduction of vascular closure devices and hemostatic pads, which were designed to significantly shorten the time it took to close the wound left at the access site.
May 19, 2011
Feature | Mike Rodman, Cath Lab Supervisor, Appleton Medical Center, Appleton, Wis., and Theda Clark Medical Center, Neenah, Wis.
According to the American College of Cardiology (ACC), each year nearly 400,000 patients are admitted to U.S. hospitals with ST segment elevation myocardial infarction (STEMI). National ACC/American Heart Association (AHA) guidelines state that hospitals treating STEMI patients with emergency percutaneous coronary interventions (PCI) should reliably achieve a door-to-balloon time (D2B) of 90 minutes or less, and studies have demonstrated strong associations between time to primary PCI and in-hospital mortality risk.
May 19, 2011News
May 19, 2011—Arterial Remodeling Technologies (ART) announced details of the state-of-the-art design of its polymer-based bioresorbable stent platform at EuroPCR 2011.
May 19, 2011© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now